Opinion on Therapy Area

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

"GreeneChip": new tool with broad use

A novel diagnostic tool, able to simultaneously screen for up to 30,000 different viruses, bacteria, fungi and parasites is currently being investigated by researchers at New York's Columbia University. Although its widespread availability requires more work, such a tool could help physicians give a more accurate diagnosis and prescribe appropriate treatment.

Published By Datamonitor
13 Dec 2006
Expert View
Expert View

"The pill" goes natural with potential new bestseller

Teva has announced the EU approval of NOMAC/E2, the first monophasic contraceptive with natural estrogen. The perceived increased safety of natural estrogen and a global launch will drive sales of the product, making it a leading hormonal contraceptive brand. To maximize its potential, however, Teva needs to show improved safety over synthetic estrogen contraceptives in post-marketing studies.

Published By Datamonitor
03 Aug 2011
CommentWire
CommentWire

'Female Viagra' tag unjustified for Boehringer Ingelheim drug

With the release of positive Phase III clinical trial data, Boehringer Ingelheim's flibanserin has been found to offer significant benefit to sufferers of hypoactive sexual desire disorder. However, lower public acceptance of the disorder and uncertain demand will restrict the drug's commercial potential.

Published By Datamonitor
20 May 2010
Expert View
Expert View

'Silent killer' osteoporosis quietly on the increase

Osteoporosis currently affects 30 million people (predominantly women) worldwide and if left untreated, can be fatal. Historically hormone replacement therapy (HRT) has been used to help prevent the bone loss that leads to osteoporosis. However recent negative study results have lead to a rapid decline in its use, which may lead to a significant increase in the prevalence of osteoporosis.

Published By Datamonitor
30 Dec 2004
Expert View
Expert View

A battle looms in mild cognitive impairment...

More than a tenth of the world's elderly people have mild cognitive impairment, representing a significant potential market. Worse, these sufferers have a 50% chance developing Alzheimer's. Although there is no approved treatment available yet, several different therapies are in development. The fight for dominance in this potentially lucrative market is about to begin - but who will win out?

Published By Datamonitor
07 Dec 2001
Expert View
Expert View

A blockbuster is born in Johnson & Johnson's Nucynta ER

Johnson & Johnson has received FDA approval for Nucynta ER in moderate to severe chronic pain. Backed by clinical trial data showing comparable efficacy and superior tolerability to the market-leading opioid, OxyContin, Nucynta ER will be a commercial success for Johnson & Johnson. Additional benefits in neuropathic pain will further strengthen the clinical argument for its use.

Published By Datamonitor
30 Aug 2011
Expert View
Expert View

A Mars a day to keep the doctor away?

Mars has unveiled a new product range that claims to satisfy chocolate lovers' cravings while also being good for the heart. With obesity on the rise, and following clampdowns on junk food in US and European schools, entering the health foods market could be a good move. However, Mars is not the only one to realize this, meaning it could face stiff competition.

Published By Datamonitor
16 Sep 2005
Expert View
Expert View

A new phase in the breast cancer battle?

Published By Datamonitor
21 Sep 2001
Expert View
Expert View

A regulatory irony

Published By Datamonitor
22 Dec 2000
Expert View
Expert View

AAN 2010: late-stage pipeline candidates take center stage in migraine

In the wake of Imitrex's and Topamax's patent expiries, announcements at this year's American Academy of Neurology meeting focused firmly on the next major breakthroughs for the acute and prophylactic migraine markets. Pooled data for candidates from Allergan and Merck & Co demonstrated impressive potential, suggesting renewed hope for sufferers.

Published By Datamonitor
20 Apr 2010

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.